Do α‑reductase inhibitors prevent prostate cancer? 2008 Practice Guideline from the American Society of Clinical Oncology and American Urological Association

2009 ◽  
Vol 119 (10) ◽  
pp. 648-653
Author(s):  
David Thüer ◽  
David Pfister ◽  
Robin Epplen ◽  
Bernhard Brehmer ◽  
Axel Heidenreich
Keyword(s):  
Prostate Cancer ◽  
Clinical Oncology ◽  
Practice Guideline ◽  
Reductase Inhibitors ◽  
American Society ◽  
American Urological Association

scholarly journals Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

2009 ◽  
Vol 27 (9) ◽  
pp. 1502-1516 ◽  
Author(s):  
Barnett S. Kramer ◽  
Karen L. Hagerty ◽  
Stewart Justman ◽  
Mark R. Somerfield ◽  
Peter C. Albertsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Clinical Oncology ◽  
Cancer Chemoprevention ◽  
Evidence Based ◽  
High Grade ◽  
Reductase Inhibitors ◽  
Potential Risks ◽  
American Society ◽  
American Urological Association

Purpose To develop an evidence-based guideline on the use of 5-α-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention. Methods The American Society of Clinical Oncology (ASCO) Health Services Committee (HSC), ASCO Cancer Prevention Committee, and the American Urological Association Practice Guidelines Committee jointly convened a Panel of experts, who used the results from a systematic review of the literature to develop evidence-based recommendations on the use of 5-ARIs for prostate cancer chemoprevention. Results The systematic review completed for this guideline identified 15 randomized clinical trials that met the inclusion criteria, nine of which reported prostate cancer period prevalence. Conclusion Asymptomatic men with a prostate-specific antigen (PSA) ≤ 3.0 ng/mL who are regularly screened with PSA or are anticipating undergoing annual PSA screening for early detection of prostate cancer may benefit from a discussion of both the benefits of 5-ARIs for 7 years for the prevention of prostate cancer and the potential risks (including the possibility of high-grade prostate cancer). Men who are taking 5-ARIs for benign conditions such as lower urinary tract [obstructive] symptoms (LUTS) may benefit from a similar discussion, understanding that the improvement of LUTS relief should be weighed with the potential risks of high-grade prostate cancer from 5-ARIs (although the majority of the Panel members judged the latter risk to be unlikely). A reduction of approximately 50% in PSA by 12 months is expected in men taking a 5-ARI; however, because these changes in PSA may vary across men, and within individual men over time, the Panel cannot recommend a specific cut point to trigger a biopsy for men taking a 5-ARI. No specific cut point or change in PSA has been prospectively validated in men taking a 5-ARI.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline

2018 ◽  
Vol 36 (32) ◽  
pp. 3251-3258 ◽  
Author(s):  
Justin E. Bekelman ◽  
R. Bryan Rumble ◽  
Ronald C. Chen ◽  
Thomas M. Pisansky ◽  
Antonio Finelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Practice Guideline ◽  
Radiation Oncology ◽  
Expert Panel ◽  
Scientific Evidence ◽  
Localized Prostate Cancer ◽  
Urologic Oncology ◽  
American Society ◽  
American Urological Association

Purpose In April 2017, the American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Clinically Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. Results The ASCO Expert Panel determined that the recommendations from the Clinically Localized Prostate Cancer guideline were clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Clinically Localized Prostate Cancer guideline except for two recommendations on cryosurgery. The two recommendations covering cryosurgery were not endorsed because the panel found that there is insufficient evidence to support the use of cryotherapy in this setting. Recommendations The ASCO Expert Panel endorsed all but two of the original guideline recommendations as written and offered a series of discussion points to guide practice.

Sign in / Sign up

Export Citation Format

Share Document